PDCD1 and melanoma: In a phase II–III, global, double-blind, randomized trial, patients with previously untreated metastatic or unresectable melanoma receiving relatlimab (a LAG-3-blocking antibody) plus nivolumab (a PD-1-blocking antibody) had dramatically longer PFS than those receiving nivolumab alone (median PFS 10.1 vs. 4.6 months, P = 0.006) [20].